GenomtecWAR:GMT -0.10%30 Net Current Asset Value is zł0.09 as of Mar. 2026, which is 100% below its 10-year median of 34.11. GuruFocus rates WAR:GMT with a GF Score™ of 30/100. The stock has 4 warning signs investors should review. Among 569 Medical Devices & Instruments companies, Genomtec ranks worse than 94.9% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Genomtec's net current asset value per share for the quarter that ended in Mar. 2026 was zł0.09.
The historical rank and industry rank for Genomtec's Net Current Asset Value or its related term are showing as below:
WAR:GMT'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 16.42 Med: 34.11 Max: 253.33
Current: 53.28
During the past 8 years, the highest Price-to-Net-Current-Asset-Value Ratio of Genomtec was 253.33. The lowest was 16.42. And the median was 34.11.
WAR:GMT's Price-to-Net-Current-Asset-Value is ranked worse than 94.9% of 569
companies
in the Medical Devices & Instruments industry
Industry Median: 4.99
vs WAR:GMT: 53.28
Genomtec (WAR:GMT) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Genomtec Net Current Asset Value Related Terms
Genomtec Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Genomtec's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:GMT vs ABT, SYK, MDT: Net Current Asset Value Comparison
For the Medical Devices subindustry, Genomtec's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genomtec Price-to-Net-Current-Asset-Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Genomtec's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Genomtec's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of zł0.09 mean?
Genomtec (WAR:GMT) has a Net Current Asset Value of zł0.09 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Genomtec and its competitors. This is 100% below median its historical median of 34.11. Over the past decade, Genomtec's Net Current Asset Value has ranged from 16.42 to 253.33. According to the industry distribution chart, Genomtec ranks #540 out of 569 companies in the Medical Devices & Instruments industry, placing it in the top 94.9%.
Is Genomtec's Net Current Asset Value too high?
Genomtec's current Net Current Asset Value of zł0.09 is 100% below median its 10-year median of 34.11. Over the past 10 years, this metric has ranged from a low of 16.42 to a high of 253.33. Based on the distribution chart, Genomtec ranks #540 out of 569 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Genomtec has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Genomtec's Net Current Asset Value compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Genomtec ranks #540 out of 569 companies for Net Current Asset Value. This places Genomtec in the lower half of its industry. The industry median Net Current Asset Value is 4.99. Historically, Genomtec's own Net Current Asset Value has ranged from 16.42 to 253.33 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Medical Devices & Instruments company?
The median Net Current Asset Value among Medical Devices & Instruments companies is 4.99, based on 569 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Genomtec and its competitors. For the Medical Devices & Instruments industry, the median Net Current Asset Value is 4.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genomtec's current Net Current Asset Value is zł0.09, which is 100% below median its own 10-year median of 34.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomtec stock overvalued right now?
Genomtec (WAR:GMT) has a current Net Current Asset Value of zł0.09. The current Net Current Asset Value is zł0.09, which is 100% below median its 10-year median of 34.11. Genomtec's overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Genomtec (WAR:GMT), the current Net Current Asset Value is zł0.09 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Genomtec SA is an technology company which works in the area of ?? molecular diagnostics. It is a manufacturer of mobile molecular analyzers. The device are designed to identify pathogens including viruses, bacteria, and fungi by amplifying and detecting specific DNA and RNA fragments.
30GF Score
Get the complete analysis for WAR:GMT
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:GMT has been successfully added to your 
